TTK

Dual specificity protein kinase TTK

83,802 patent compounds predicted against TTK, 47,640 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL104312	1.00	20/20
SCHEMBL104317	1.00	20/20
SCHEMBL104472	1.00	20/20
SCHEMBL104765	1.00	20/20
SCHEMBL105020	1.00	20/20
SCHEMBL105196	1.00	20/20
SCHEMBL137089	1.00	20/20
SCHEMBL104910	0.90	20/20
SCHEMBL135281	0.88	20/20
SCHEMBL104134	0.87	20/20
SCHEMBL104724	0.85	20/20
SCHEMBL104887	0.82	20/20
SCHEMBL104544	0.81	20/20
SCHEMBL104539	0.79	20/20
SCHEMBL134558	0.78	20/20
SCHEMBL134559	0.77	20/20
SCHEMBL104538	0.77	20/20
SCHEMBL105105	0.77	20/20
SCHEMBL178456	0.77	20/20
SCHEMBL178466	0.77	20/20

Germline variants in TTK on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full TTK gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to TTK by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer	PHASE2	RECRUITING
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Protein Tyrosine Kinases (PTK) in Multiple Myeloma	PHASE2	COMPLETED
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations	PHASE2	COMPLETED
Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors	PHASE1/PHASE2	RECRUITING
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy	PHASE2	COMPLETED
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer	PHASE2	UNKNOWN
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...	PHASE2	COMPLETED
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.	PHASE2	UNKNOWN
Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy	PHASE2	COMPLETED
Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma	PHASE1/PHASE2	COMPLETED
PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP	PHASE1/PHASE2	COMPLETED
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma	PHASE2	ACTIVE_NOT_RECRUITING
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors	PHASE2	RECRUITING
A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
A Study of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid Tumors	PHASE1	UNKNOWN
Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency	PHASE1	RECRUITING
Nilotinib in Huntington's Disease	PHASE1	UNKNOWN
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101	PHASE1	WITHDRAWN
Phase I Study of AT13148, a Novel AGC Kinase Inhibitor	PHASE1	COMPLETED
Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel	PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Androgenetic Alopecia and the JAK-STAT Pathway	nan	COMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING
Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a TTK binder may also engage these)

Protein	Name	Similarity
Q4R945	—	1.000	Q4R945 →
P35761	—	1.000	P35761 →
Q8AYG3	—	0.994	Q8AYG3 →
B2GUY1	—	0.990	B2GUY1 →
Q2QMH1	—	0.989	Q2QMH1 →
Q8WZ64	—	0.988	Q8WZ64 →
O94235	—	0.988	O94235 →
P62292	—	0.987	P62292 →
Q8RXT4	—	0.987	Q8RXT4 →
Q68FF0	—	0.987	Q68FF0 →
Q8BZ05	—	0.987	Q8BZ05 →
P62291	—	0.987	P62291 →
Q08AX9	—	0.987	Q08AX9 →
Q6GN21	—	0.986	Q6GN21 →
Q9FT70	—	0.986	Q9FT70 →
Q6YY75	—	0.986	Q6YY75 →
Q6PIW4	—	0.986	Q6PIW4 →
Q6DDJ5	—	0.986	Q6DDJ5 →
Q9FY74	—	0.986	Q9FY74 →
Q5HZN1	—	0.986	Q5HZN1 →
Q4R8Y1	—	0.986	Q4R8Y1 →
CDC7	Cell division cycle 7-related protein kinase	0.986	landscape →
BRDT	Bromodomain testis-specific protein	0.985	landscape →
BLM	RecQ-like DNA helicase BLM	0.985	landscape →
BUB1	Mitotic checkpoint serine/threonine-protein kinase BUB1	0.985	landscape →
Q9NQW6	—	0.985	Q9NQW6 →
Q8RX66	—	0.985	Q8RX66 →
P62290	—	0.985	P62290 →
Q94CU5	—	0.985	Q94CU5 →
A2VDZ4	—	0.985	A2VDZ4 →